. . . . . . . . . "a(SCHEM:\"Advanced Glycation End Product\") -> path(SDIS:\"tissue damage\")" . "Approximately 61,000 statements." . "Copyright (c) 2011-2012, Selventa. All rights reserved." . "BEL Framework Large Corpus Document" . . "20131211" . "The association of galectin-3 ablation with enhanced susceptibility to AGE-induced renal disease, increased AGE levels and signaling, and altered AGE-receptor pattern indicates that galectin-3 is operating in vivo as an AGE receptor to afford protection toward AGE-dependent tissue injury." . . "Selventa" . . . . "2014-07-03T14:32:31.017+02:00"^^ . . .